Evidence map›Paper›PMID 38789647›Full record

ArticleNature medicine2024

Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.

Jordi Rodón, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese and 5 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Jordi RodónThe University of Texas MD Anderson Cancer Center, Houston, TX, USA. jrodon@mdanderson.org.ORCID http://orcid.org/0000-0001-6467-3632
Silvia DamianFondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID http://orcid.org/0000-0001-9560-1092
Muhammad FurqanUniversity of Iowa, Iowa City, IA, USA.
Jesús García-DonasCentro Integral Oncologico Clara Campal, Madrid, Spain.ORCID http://orcid.org/0000-0001-7731-3601
Hiroo ImaiTohoku University Hospital, Sendai-Shi, Japan.
Antoine ItalianoInstitut Bergonié, Bordeaux, France.ORCID http://orcid.org/0000-0002-8540-5351
Iben SpanggaardRigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.ORCID http://orcid.org/0000-0001-5925-2630
Makoto UenoKanagawa Cancer Center, Yokohama, Japan.
Tomoya YokotaShizuoka Cancer Center, Shizuoka, Japan.ORCID http://orcid.org/0000-0001-7327-7949
Maria Luisa VeroneseIncyte International Biosciences Sàrl, Morges, Switzerland.
Natalia OliveiraIncyte International Biosciences Sàrl, Morges, Switzerland.
Xin LiIncyte Corporation, Wilmington, DE, USA.
Aidan GilmartinIncyte Corporation, Wilmington, DE, USA.
Michael SchafferIncyte Corporation, Wilmington, DE, USA.ORCID http://orcid.org/0000-0003-1381-0275
Lipika GoyalMass General Cancer Center, Harvard Medical School, Boston, MA, USA. lgoyal@stanford.edu.ORCID http://orcid.org/0000-0002-9777-6221

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Douglas Robert Spitz · 2000 to 2026
$70.0M
NCI NIH HHS P30 CA086862
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38789647
PMCPMC11333269

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.